Testosterone therapy: a friend or a foe for the aging men with benign prostatic hyperplasia?

Giulia Rastrelli1, Linda Vignozzi1,2, Mario Maggi1,2,3

Asian Journal of Andrology (2019) 21, 1–3; doi: 10.4103/aja.aja_86_19; published online: 16 August 2019

One of the major concerns for the prescription of medications containing testosterone (T) in the aging men with T deficiency (TD) is prostate disorders (such as benign prostatic hyperplasia, BPH) and their related symptoms (lower urinary tract symptoms, LUTS). This is because prostate is an androgen-responsive gland; however, the androgen dependence of prostate growth, well demonstrated in earlier phases of life, has no clear evidence in late adulthood and senescence. In fact, after the age of 40 years, BPH becomes increasingly more prevalent. On the other hand, in men older than 40 year, a progressive decline in T is observed. These epidemiological data are a starting point for questioning a putative detrimental role of T on the prostate health in the ageing man.

In addition, even the administration of supraphysiological doses of T in adult healthy men with or without dutasteride did not result in a significant change in prostate volume over 20 weeks of treatment.1 Based on this evidence, it is not surprising that epidemiological studies failed to demonstrate that BPH is associated with higher serum T.2 Conversely, there is even an evidence of a negative relationship between T and BPH. In a derivative study of the Prostate Cancer Prevention Trial, involving 1417 men free from BPH, lower total T at baseline predicted the occurrence of BPH over 7 years of follow-up.3 Similarly, low T was found as a predictor of worsening in LUTS in the Florey Adelaide Male Ageing Study and in the Rancho Bernardo Study, lasting 5 years and 20 years, respectively.4,5

TD in midlife and senescence is a relatively common finding, with a prevalence of about 15% in the general population.6 Metabolic conditions included in the construct of metabolic syndrome (MetS) are common causes of TD in adulthood, and, among men with MetS, the prevalence of low T is at least doubled.7 Interestingly, in men with MetS, the prevalence of BPH is also increased.8 Evidence from epidemiological studies of a mutual association among MetS, low T, and BPH is a sound basis for hypothesizing that these three conditions are part of a single clinical picture. Amounting evidence in support to this hypothesis is provided by experimental preclinical studies.

It is important to underline that, before being a hyperplastic condition, BPH is an inflammatory disease with peculiar features. Within prostate tissue, consequent to proinflammatory stimuli whose nature is still only partially known, a progressive shift from acute to chronic histopathological characteristics of inflammation is documented. Prostatic chronic inflammation occurring in BPH is characterized by the secretion of interleukins (IL), such as IL-4, IL-13, IL-17, and IL-15, typical of a Th2 or Th17 immune response.9 In addition, besides specialized immunocompetent cells, prostatic stromal cells have the potential to become antigen-presenting cells (APC), and, accordingly, it has been demonstrated that they are able to activate CD4+ T lymphocytes.10 In turn, the activated lymphocytes secrete cytokines and growth factors, which self-maintain the inflammatory process and favor the proliferation of stromal cells leading to BPH.10

This peculiar pattern of secretion and mutual stimulation by lymphocytes and stromal BPH cells is demonstrated by in vitro studies using conventional inflammatory stimuli, such as lipopolysaccharide or tumor necrosis factor-alpha (TNF-alpha).11 However, similar responses are produced by stimulating stromal BPH cells with oxidized low-density lipoproteins (oxLDL).12 This is an interesting finding, because it could provide a possible link to explain the epidemiological association between MetS and BPH. In fact, observational clinical studies have pointed out that, among the components of MetS, dyslipidemia is most strongly associated with the extent of inflammation. This has been found in patients who have an overt and advanced prostatic disease. In prostatic tissue samples from 244 men undergoing surgery for BPH, the histopathological inflammatory score was increasingly higher as the number of components of MetS increased, with the strongest association documented for hypertriglycerideremia and lower high-density lipoprotein (HDL) cholesterol.13 Interestingly, the relationship between dyslipidemia and prostatic inflammation has been observed also in younger men without an overt BPH. In a population of men undergoing a medical consultation for couple infertility, a greater prostate volume, as assessed by transrectal ultrasound, was associated with lower HDL cholesterol.14

In this context, a rabbit model of MetS induced by a high-fat diet (HFD) represents a useful experimental tool for the investigation of the causative role of MetS on BPH. In HFD animals, prostate was characterized by histopathological features of inflammation, fibrosis, and hypoxia, resembling the characteristics of BPH observed in humans.15 Interestingly, Figure 1, expanding previously reported data,16 shows that, in rabbit prostate, the gene expression of markers of inflammation is higher as cholesterol levels increase. It is noteworthy that, in HFD
Association between total cholesterol (log scale) and expression of several inflammation-related genes in the prostate of rabbits fed for 12 weeks a RD (open circles) or a HFD (open diamonds). Gene expression was performed by quantitative RT-PCR analysis in the prostate samples of the aforementioned experimental animals and calculated according to comparative C_r method by rRNA subunit 18S as the reference gene for normalization. Results in the Y-axis are reported as the level of mRNA expression in percentage over the mean value of the RD group. Statistics in each panel are derived from univariate analysis and reported as Spearman’s coefficient with the level of significance and number of experimental animals. RD: regular diet; HFD: high-fat diet; RT-PCR: real-time polymerase chain reaction; rRNA: ribosomal ribonucleic acid; CD4+: cluster of differentiation 4; IL-6: interleukin 6; IL-8: interleukin 8; TNF-alpha: tumor necrosis factor-α; RAGE: receptor for advanced glycation end products; STAMP2: six transmembrane protein of prostate 2; MMP-9: matrix metalloproteinase 9; T-box transcription factor; ITGAX: integrin alpha X.

Figure 1: Association between total cholesterol (log scale) and expression of several inflammation-related genes in the prostate of rabbits fed for 12 weeks a RD (open circles) or a HFD (open diamonds). Gene expression was performed by quantitative RT-PCR analysis in the prostate samples of the aforementioned experimental animals and calculated according to comparative C_r method by rRNA subunit 18S as the reference gene for normalization. Results in the Y-axis are reported as the level of mRNA expression in percentage over the mean value of the RD group. Statistics in each panel are derived from univariate analysis and reported as Spearman’s coefficient with the level of significance and number of experimental animals. RD: regular diet; HFD: high-fat diet; RT-PCR: real-time polymerase chain reaction; rRNA: ribosomal ribonucleic acid; CD4+: cluster of differentiation 4; IL-6: interleukin 6; IL-8: interleukin 8; TNF-alpha: tumor necrosis factor-α; RAGE: receptor for advanced glycation end products; STAMP2: six transmembrane protein of prostate 2; MMP-9: matrix metalloproteinase 9; T-box transcription factor; ITGAX: integrin alpha X.

These experimental data suggest that T is a friend, rather than a foe, for prostate health even in BPH conditions. However, it should be noted that opposite evidence supporting an adverse effect of T on the prostate and LUTS is present. In an experimental rat model, the treatment with DHT with or without estradiol was able to induce a significant increase of prostate volume and decrease of urine volume voided as compared with controls. In addition, the clinical success in improving LUTS of the 5α-reductase inhibitors (5ARIs), which decrease circulating and intraprostatic DHT levels, is well proven by clinical trials. Nonetheless, this does not contrast with the aforementioned beneficial role of T on the prostate. Indeed, 5ARIs decrease prostate volume, and they have been associated with an increased grade of prostatic inflammation, as compared with placebo, further suggesting the anti-inflammatory role of T. Hence, it is conceivable that the androgen deprivation and the androgen supplementation may act on LUTS by different mechanisms, the former reducing the prostate volume and the latter modulating the inflammatory process.

Supporting evidence from clinical studies for a beneficial role of T on the prostate is still circumstantial. Observational longitudinal studies evaluating prostatic outcomes almost consistently found an improvement in LUTS and residual urinary volume, without any significant change in prostate volume. However, it is important to underline that these studies often involve small samples observed for short follow-up periods. In addition, they usually employ less standardized protocols of data collection, and, even more importantly, the assignment to the treated or untreated arms is arbitrary rather than randomized, thus possibly resulting in allocation bias.

Although randomized clinical trials (RCT) did not provide such enthusiastic results, it should be noted that none of these found any worsening in LUTS, as recently shown by a meta-analysis of 14 RCTs including overall 2029 men with TD with borderline-low T levels and further confirmed by a more recent meta-analysis evaluating studies, which enrolled only men with unequivocally low serum T. Besides the assessment of subjective outcomes, only a few RCTs evaluated objective prostatic parameters in TD men treated with T. In particular, data on the effect of T therapy (TTh) on prostatic inflammation are lacking. Recently, preliminary data from a RCT, including 120 men with MetS and BPH, showed that a 6-month treatment with T gel 5 g daily, administered to hypogonadal men, is able to improve ultrasound markers of prostatic inflammation as well as the expression of inflammation-related genes, such as cyclooxygenase-2, monocyte chemokine protein 1 (MCP1), and related orphan receptor gamma-t (RORγt).
According to the available evidence, the concerns on the use of TTh in men with BPH and LUTS have no supportive experimental basis. BPH can be considered part of the constellation of derangements occurring in MetS. TD associated with MetS has the potential to exacerbate prostatic inflammation occurring in MetS. Although specifically designed RCTs are needed, it is likely that, in the next future, we will assist to a transition of TTh from the side of the enemies of the prostate to that of the allies.

**AUTHOR CONTRIBUTIONS**
GR and MM conceived the article and designed the methodology; GR and LV collected the data; GR drafted the article; GR, LV, and MM revised and edited the final article. All authors read and approved the final manuscript.

**COMPETING INTERESTS**
All authors declared no competing interests.

**REFERENCES**
1. Bhasin S, Travison TG, Storer TW, Lakshman K, Kaufsh M, et al. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012; 307: 931–9.
2. Lee JH, Kim Y, Park YW, Lee DG. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men. J Sex Med 2014; 11: 1309–15.
3. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008; 168: 1416–24.
4. Trifilo MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010; 105: 1554–9.
5. Martin S, Lange K, Haren MT, Taylor AW, Wittert G, et al. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 2014; 191: 130–7.
6. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, et al. Hypogonadism and metabolic syndrome. J Endocrinol Invest 2011; 34: 557–67.
7. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, et al. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest 2014; 37: 313–22.
8. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012; 214: 31–43.
9. Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013; 73: 789–800.
10. Lotti F, Corona G, Vignozzi L, Rossi M, Maseroli E, et al. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl 2014; 16: 295–304.
11. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012; 212: 71–84.
12. Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol 2015; 418: 120–33.
13. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16: 626–38.
14. Constantino CE. Influence of hormone treatment on prostate growth and micturition characteristics of the rat. Prostate 1996; 29: 30–5.
15. Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Bleeck L, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REDuction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Urology 2011; 78: 641–6.
16. Kim EH, Brockman JA, Andriole GL. The use of 5alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol 2018; 5: 28–32.
17. Murtoja TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM, et al. Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2016; 25: 463–9.
18. Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and benign prostatic hyperplasia. Sex Med Rev 2019; 7: 259–71.
19. Kohn TP, Mata DA, Ramasamy R, Lipshtiz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol 2016; 69: 1083–90.
20. Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, Serrano V, Singh-Ospina N, et al. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Endocrinol Metab 2018; 103: 1745–54.
21. Rastrelli G, Cipriani S, Lotti F, Cellai I, Comeglio P, et al. Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic syndrome and hypogonadism: preliminary results from a randomized placebo-controlled clinical trial. J Sex Med 2018; 15: S160.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
©The Author(s)(2019)